New Enterprise Associates 17, L.P. bought $2.3M of KRRO
owner at Korro Bio, Inc.. 207,100 shares at an average of $11.11, traded Mar 10, 2026, filed Mar 12, 2026.
Score components
- +12Role10% owner
- +25Trade size$2.3M at market
- +3Relative to holdingsHoldings up 19%
- +8Price context78% below the 52-week high
- +15Cluster9 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +10.3%, 3m -8.4%, 6m +13.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-104719, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 10, 2026 | POpen-market purchase Common Stock | +207,100 | $11.11 | $2.3M | 1,297,893 | Mar 12, 2026 |
| Mar 10, 2026 | POpen-market purchase Pre-Funded Warrantsderivative | +242,945 | $11.11 | $2.7M | 242,945 | Mar 12, 2026 |
Related signals
Other insiders at Korro Bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 24Weak | Korro Bio, Inc. | Jean Francois Formela director | $686k 48,690 shares | -7% | |
| 3Weak | Korro Bio, Inc. | Oliver Dolan Senior Vice President, Finance | $69 5 shares | -0% | |
| 23Weak | Korro Bio, Inc. | Oliver Dolan Senior Vice President, Finance | $99k 7,353 shares | -31% | |
| 40Moderate | Korro Bio, Inc. | Jean Francois Formela director | $2.5M 171,405 shares | -18% | |
| 43Moderate | Korro Bio, Inc. | Jeffrey Cerio General Counsel | $72k 6,609 shares | -16% | |
| 46Moderate | Korro Bio, Inc. | Todd Chappell Chief Operating Officer | $34k 3,168 shares | -16% | |
| 41Moderate | Korro Bio, Inc. | Oliver Dolan Senior Vice President, Finance | $37k 3,383 shares | -16% | |
| 41Moderate | Korro Bio, Inc. | Loic A Vincent Chief Scientific Officer | $37k 3,418 shares | -16% | |
| 50Moderate | Korro Bio, Inc. | Ram Aiyar President and CEO | $197k 15,152 shares | -17% | |
| 9Weak | Korro Bio, Inc. | Jean Francois Formela director | $40k 2,860 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.